Core Viewpoint - Definitive Healthcare, a leader in healthcare market data and analytics, will have its CFO, Casey Heller, present at the 28th Annual Needham Growth Conference on January 14, 2026 [1][2]. Company Overview - Definitive Healthcare specializes in data and analytics focused on the business side of healthcare, aiming to simplify the complex healthcare market and provide insights for strategic decision-making [3].

Core Viewpoint - Health Catalyst, Inc. has appointed Matt Arens, CEO and Founder of First Light Asset Management, to its board of directors, effective December 1, 2025, which is expected to enhance the company's strategic focus and shareholder value creation efforts [1][3]. Company Overview - Health Catalyst is a leading provider of data and analytics technology and services aimed at improving healthcare outcomes, with over 1,100 organizations relying on its offerings [6]. - The company operates a cloud-based technology ecosystem called Health Catalyst Ignite™, which provides AI-enabled data and analytics solutions [6]. Shareholder Information - First Light Asset Management is the largest shareholder of Health Catalyst, owning approximately 19% of the company's outstanding shares, which equates to about 13.9 million shares [2]. - Matt Arens has been a shareholder since Health Catalyst's IPO in 2019 [2]. Board Composition - The addition of Matt Arens to the board is seen as a significant move due to his extensive experience in capital markets and healthcare investments [3]. - Matthew Kolb, a current director since 2023, will not seek re-election at the 2026 annual meeting, marking a change in board composition [5]. Strategic Insights - Matt Arens expressed that the market is not fully recognizing the value within Health Catalyst, citing a low EBITDA multiple and high free cash flow generation potential as indicators of significant appreciation opportunities for the company's shares [5]. - The firm has a proven track record of delivering billions of dollars in measurable results, reinforcing its commitment to data-informed healthcare improvement [6].

Core Insights - OneMedNet Corporation has achieved significant adoption by a leading global medical device company, recognized for its advancements in diagnostic imaging and digital health solutions [1] - The company has established a master services agreement that allows for ongoing engagement without a fixed term, including multiple purchase orders for Real-World Data [2] - OneMedNet's ability to provide comprehensive, multimodal data sets is emphasized as a key factor in generating Real-World Evidence, which is crucial for AI model development in medical imaging [3] Company Overview - OneMedNet is positioned as a leader in harnessing Real-World Data (RWD) through its iRWD™ platform, which taps into data from over 1,750 healthcare sites [5] - The company focuses on delivering curated, de-identified datasets that empower clients to enhance AI development, clinical trial design, and healthcare outcomes [4] - Beyond healthcare, OneMedNet's proprietary AI technology is applicable in other industries such as finance, retail, and telecom, showcasing its versatility [6]

Core Insights - OneMedNet Corporation has achieved a greater than 25% expansion of its proprietary iRWD™ network and platform, enhancing its operational capacity and growth trajectory with the addition of over 5 billion administrative records [1][8] - The company is responding to the rising demand for high-quality longitudinal data and insights into health economics and social determinants of health, particularly for underserved populations [2][8] - OneMedNet's iRWD™ network now includes over 1,750 healthcare sites, providing access to 34 million patients and 136 million clinical exams, positioning the company for significant revenue growth through increased data licensing and enterprise partnerships [8] Company Overview - OneMedNet is a leader in AI-powered Real-World Data (RWD), utilizing its iRWD™ platform to harness data from healthcare sites, which fuels innovation in drug development and medical devices [5] - The company emphasizes the importance of clinical integrity in Real-World Evidence, enabling stakeholders in life sciences and healthcare to generate actionable insights reflective of real-world care delivery [4] - The RWE industry is valued at $60 billion, and OneMedNet aims to be at the forefront of this transformation, making evidence generation faster and more effective [4] Market Position - The expansion of OneMedNet's network reinforces its position as a premier data partner, laying the foundation for accelerated revenue generation and customer acquisition [3][8] - The company’s proprietary AI technology anonymizes data for various industries, including finance and retail, showcasing its versatility beyond healthcare [6]

Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $59.2 million, down 7% year over year, but above the high end of guidance [5][21] - Adjusted EBITDA was $14.7 million, representing a 25% margin, which was well ahead of expectations [6][21] - Unlevered free cash flow for the trailing twelve months was $67.1 million, down 12% year over year, with a 91% conversion from adjusted EBITDA [27][28] Business Line Data and Key Metrics Changes - Subscription revenue declined 7% year over year, while Professional Services revenue grew 9% in the quarter [23] - Adjusted gross profit was $47.1 million, down 11% from Q1 2024, with a gross profit margin of 79.5% [23] - Adjusted operating income was $12 million, down 35% from Q1 2024, with an operating income margin of 20% [26] Market Data and Key Metrics Changes - New logo activity was solid across all end markets, indicating ongoing demand for differentiated actionable data [7] - Renewal rates stabilized in Q1 at levels observed in the second half of 2024, but retention rates remain lower than desired [7][8] Company Strategy and Development Direction - The company is focusing on four strategic pillars: differentiated data, seamless integration, customer success, and digital engagement [9][18] - There is a commitment to improving retention rates and enhancing the value proposition through targeted investments in data quality and customer engagement [18][25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in operational strategies despite lower retention rates, indicating a lag in seeing the positive impacts of changes made [8][19] - The company remains on track to meet full-year financial targets, with expectations for sequential revenue growth in the near term [19][33] Other Important Information - The company experienced a goodwill impairment of $176.5 million due to stock price decline, which is a non-cash accounting charge [29] - The company repurchased approximately 5.6 million shares for a total of $21.2 million, leaving $77 million remaining under the existing authorization [28] Q&A Session Summary Question: Can you elaborate on data integrations and challenges? - Management indicated that data sharing and integration depend on various factors, including data security and system compatibility, and they are working to facilitate these integrations [36][40] Question: What is the agency strategy and its impact on the go-to-market motion? - The agency strategy is seen as a logical next step to help customers activate data, applicable across all customer segments, with expectations for contributions this year [41][43] Question: What is the expected timeframe for seeing growth inflection? - Management anticipates seeing improvements in growth rates within the year as operational changes take effect [46][48] Question: How does the company plan to win back customers? - The company believes that high-quality data and service will create a competitive advantage, allowing them to win back former customers while also acquiring new ones [49][50] Question: What is the churn rate and competitive environment? - Churn rates were consistent with the second half of the previous year, and while there are pressures in the market, management has not observed significant changes in competitive dynamics [77][78]

As filed with the Securities and Exchange Commission on May 6, 2024 Registration No. 333-276130 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONEMEDNET CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3721 86-2049355 (Primary Standard Industrial Classification Code Number) OneMedNet Corporation 6385 Old Shady O ...